FDA's US-First Strategy: Device Center Sets Three-Year Goals
Executive Summary
A new three-year plan to implement strategic priorities at US FDA's device center aims to make several broad improvements to the medtech ecosystem. Among them is improving staff incentives at the agency, creating more partnerships with industry and other stakeholders, and improving the center's processes to make it easier for novel medical devices to enter the US market.
You may also be interested in...
Device Center Strategic Priorities: Equity, Resilience, Staff Development
The US FDA’s device center has set strategic priorities for 2022-2025 of promoting a modern and diverse workforce, enhancing organizational agility and resilience, and advancing health equity. A new report lays out how the agency plans to pursue these goals.
US FDA’s Shuren: Device Center Will Roll Out New Strategic Priorities In 2022
Center for Devices and Radiological Health director Jeff Shuren said on 22 July that the center is incorporating lessons learned from the COVID-19 pandemic and its ongoing user-fee negotiations with industry into its upcoming set of strategic goals.
US FDA Recognizes Case For Quality Collaborative Community
The Case for Quality Collaborative Community – or CfQcc – affords stakeholders across industry a safe space where they can rally around an array of topics to advance medical device quality and safety.